Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders

 
• By Alaric DeArment

Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.

Cancer-cells-pink-color_1200x675
Nektar and BMS announced the failure of their Phase III melanoma study • Source: Shutterstock

More from Clinical Trials

More from R&D